1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

US Proposed Rule For OTC Hearing Aid Access Excites Eargo – Across Industry, Not So Much

 
• By Brian Bossetta

CEO of direct-to-consumer hearing aid manufacturer Eargo says an OTC category for hearing aids would improve the quality of life for many consumers with hearing loss.

EARGO hearing aids
EARGO TOUTS ITS HEARING AIDS AS VIRTUALLY INVISIBLE. • Source: Eargo

The US hearing aid industry fails to reach much of its potential market with devices available only by prescription, says Christian Gormsen, CEO of Eargo Inc., which is anxious for the Food and Drug Administration's publication of a final rule for OTC sales of hearing aids for mild to moderate hearing loss. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Criticism Of US Progress On Sunscreen Ingredient Innovation Demands OMUFA Hearing Spotlight

 
• By Malcolm Spicer

Discussion of introducing additional OTC sunscreen ingredients escaped a total eclipse criticism of Trump’s health agency layoffs caused. Comments and questions by Republican members joined by several Democrats and focused testimony and answers by witnesses representing the industry and public health groups spotlighted sunscreen.

Pharma Exhales, Dodges Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.

Eisai Switches Proton Pump Inhibitor Rabeprazole To OTC In Japan

 
• By David Ridley

Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.